Product Images Rivastigmine Transdermal System

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 20 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 51991-898 by Breckenridge Pharmaceutical, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - rivastigmine 01

Chemical Structure - rivastigmine 01

Figure 1 - rivastigmine 02

Figure 1 - rivastigmine 02

Figure 2 - rivastigmine 03

Figure 2 - rivastigmine 03

This is a table showing the concentration of Rivastigmine medication in ng/mL for different dosage strengths (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) based on the number of patients (n) in each group (19, 22, and 22 respectively).*

Figure 3 - rivastigmine 04

Figure 3 - rivastigmine 04

Figure 4 - rivastigmine 05

Figure 4 - rivastigmine 05

Figure 5 - rivastigmine 06

Figure 5 - rivastigmine 06

Figure 6 - rivastigmine 07

Figure 6 - rivastigmine 07

Figure 7 - rivastigmine 08

Figure 7 - rivastigmine 08

This is a statistical analysis of a treatment using Rivastigmine Transdermal System at different dosages. The table presents LS mean differences in improvement along with p-values for statistical significance. The graph shows the results of weeks of treatment for the different dosages. The analysis is based on an adjusted analysis of covariance model.*

Figure 8 - rivastigmine 09

Figure 8 - rivastigmine 09

This is a clinical study regarding the effects of Rivastigmine Transdermal System on cognitive improvement. The study lasted for 16 weeks with two different treatment options (15 cm? and 5 cm?). The results were analyzed using least squares means (LS means) and standard errors, indicating statistical significance at a level of 0.05.*

Figure A - rivastigmine 10

Figure A - rivastigmine 10

Figure B - rivastigmine 11

Figure B - rivastigmine 11

This appears to be a list of body parts where a measurement or marking could be taken. There is no further information provided.*

Figure C - rivastigmine 12

Figure C - rivastigmine 12

Figure D - rivastigmine 13

Figure D - rivastigmine 13

Figure E - rivastigmine 14

Figure E - rivastigmine 14

Figure F - rivastigmine 15

Figure F - rivastigmine 15

Figure G - rivastigmine 16

Figure G - rivastigmine 16

Figure H - rivastigmine 17

Figure H - rivastigmine 17

This text appears to be a set of instructions for properly disposing of a "slide folded patch." The instructions indicate that the user should place the patch in the trash and then fold the sticky sides together into an empty pouch that has been saved. The user is advised to keep the pouch away from children and pets.*

PRINCIPAL DISPLAY PANEL - 4.6 mg Patch Pouch Carton - rivastigmine 18

PRINCIPAL DISPLAY PANEL - 4.6 mg Patch Pouch Carton - rivastigmine 18

This is information about the Rivastigmine Transdermal System, which contains 30 systems, with each 5 o’ system providing 9 mg Rivastgmine to deliver 46 mg Rvastgmine every 24 hours. To use, the old patch should be removed and safely discarded, and a new patch should be applied immediately from the original pouch. The patch should not be split, and any damaged or tampered patch should not be used. For further information, please visit bpin.com or call 1-800-967-3385.*

PRINCIPAL DISPLAY PANEL - 9.5 mg Patch Pouch Carton - rivastigmine 19

PRINCIPAL DISPLAY PANEL - 9.5 mg Patch Pouch Carton - rivastigmine 19

This is a medication description for Rivastigmine Transdermal System delivered via a patch containing 18mg and delivering 9.5 mg of Rivastigmine every 24 hours, meant for transdermal use only. The instructions state that the patch should be replaced every 24 hours after removal, and the used patch should be folded and discarded safely out of the reach of children. The product should be stored at a temperature of 25°C and should not be used if damaged or showing signs of tampering. There is a phone number provided for more information.*

PRINCIPAL DISPLAY PANEL - 13.3 mg Patch Pouch Carton - rivastigmine 20

PRINCIPAL DISPLAY PANEL - 13.3 mg Patch Pouch Carton - rivastigmine 20

Rivastigmine Transdermal System is a transdermal patch that delivers 13.3 mg of rivastigmine every 24 hours. The package contains 30 systems, each containing 27 mg of rivastigmine. The inactive components of the system include acrylate adhesive, acrylates copolymer, and silicon adhesive. Transdermal use is recommended, and the patch should be applied immediately after removal from the pouch. It should not be stored unpouched and must be kept out of reach of children. In case of damage or signs of tampering, do not use the patch. For further information, visit the website or call the provided number. Dosage and administration instructions can be found in the package insert.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.